Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Predictors of Treatment Outcome for Smokers With and Without Schizophrenia
This study is currently recruiting participants.
Verified by National Institute on Drug Abuse (NIDA), July 2007
Sponsored by: National Institute on Drug Abuse (NIDA)
Information provided by: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier: NCT00501007
  Purpose

The primary purpose of this investigation is to determine the predictive value of task persistence as measured by a mirror tracing task. A secondary purpose is to evaluate differences in task persistence in smokers with or without schizophrenia. It is hypothesized that task persistence in smokers in both diagnostic categories (schizophrenia and no schizophrenia) will predict tobacco dependence treatment outcome at one and six months. It is also hypothesized that smokers with schizophrenia will show lower levels of task persistence after controlling for other motor skills than smokers without schizophrenia.


Condition Phase
Tobacco Dependence
Phase I

MedlinePlus related topics: Schizophrenia
U.S. FDA Resources
Study Type: Observational
Study Design: Longitudinal, Defined Population, Prospective Study
Official Title: Predictors of Treatment Outcome for Smokers With and Without Schizophrenia

Further study details as provided by National Institute on Drug Abuse (NIDA):

Estimated Enrollment: 160
Study Start Date: February 2005
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Current smokers must be over the age of 18,
  • Must fit into the diagnostic groups schizophrenia / schizoaffective disorder; or the non-schizophrenia group.
  • Must smoke at least 10 cigarettes per day
  • Must be capable of giving informed consent as measured by Folstein Mini Mental Status Exam of at least 22.

Exclusion Criteria:

  • Those unable to give informed consent.
  • Psychotic disorders other than schizophrenia
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00501007

Contacts
Contact: Marc L. Steinberg, PH.D. 732-235-3362 marc.steinberg@umdnj.edu

Locations
United States, New Jersey
UMDNJ Tobacco Dependence Clinic Recruiting
New Brunswick, New Jersey, United States, 08901
Sponsors and Collaborators
Investigators
Principal Investigator: Marc L. Steinberg, PH.D University of Medicine and Dentistry New Jersey
  More Information

Study ID Numbers: K23 DA018203
Study First Received: July 11, 2007
Last Updated: July 12, 2007
ClinicalTrials.gov Identifier: NCT00501007  
Health Authority: United States: Federal Government

Study placed in the following topic categories:
Schizophrenia
Mental Disorders
Tobacco Use Disorder
Substance-Related Disorders
Disorders of Environmental Origin
Psychotic Disorders
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on January 14, 2009